Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and PK of GDC-0134 in Healthy Females
NCT03237741Phase 1Completed
- Sponsor
- Genentech
- Start
- Aug 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GDC-0134 in amyotrophic lateral sclerosis (ALS) (4 arms), sponsored by Genentech. Primary endpoints: Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity at Day 22, Area Under the Plasma Concentration-Time Curve up to Time Tau at Day 22 and 3 more. Started Aug 2017; status: completed.
02
Drugs
GDC-0134
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03237741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03237741.